Given the high frequency of malignant mammary tumours, the search for new therapeutic
strategies that place growth control and neoplastic dissemination with lower adverse reactions
to the patient is growing. In this context, it aimed to evaluate the effects of medicinal ozone as
integrative therapy on the oxidative profile, response to treatment and quality of life with
mammary neoplasia undergoing conventional chemotherapy with carboplatin. Twenty -five
dogs were selected and studied, all with histopathological diagnosis of malignant mammary
neoplasia, divided into two experimental groups: GC, composed of carboplatin only (n = 11)
and GO3 - consisting of the carboplatin-treated dogs associated with ozone therapy (n = 14).
All dogs were submitted to clinical, laboratory, mastectomy, clinical-pathological
characterization of the tumour, carboplatin chemotherapy (QT), total oxidizing capacity
analysis (TAC), malondialdehyde concentration (MDA), as well as the evaluation of the
Survival, rate quality of life scores and graduation of adverse reactions resulting from
chemotherapy. Blood samples for antioxidant profile evaluations were collected 48 hours
before the first chemotherapy session (moment A), 48h before the fourth session (moment B)
and 45 days after the sixth chemotherapy session (moment C). Adverse reactions and quality
of life scores were evaluated two h before each session. The results indicated, in the GO3, the
highest concentration of red blood cells after the 2nd QT session (p = 0.017) and platelets after
the 2nd (p = 0.046), 3rd (p = 0.009) and 6th (p = 0.004) QT sessions; In the GC group, total
leukocyte values in the 1st Qt (p = 0.001), 3rd Qt (p = 0.038), 4th (p = 0.030), 5th Qt (p = 0.018)
and 6th qt (p = 0.006) and segmented neutrophils after the 1st Qt (p = 0.001), 2nd Qt (p =
0.018), 3rd Qt (P = 0.049), 5th Qt (p = 0.006) and 6th Qt (p = 0.016). There was an increase in
quality of life in both groups. Differences were observed between the quality-of-life scores
between the groups and within each group, being the largest final scores observed in the GO3
group in the 2nd QT (p = 0.002), 4th QT (p = 0.005), 5th QT (p = 0.005) and 6th QT (p <0.001).
Adverse reactions, classified exclusively, were less intense and frequent in the ozone group,
such as grade I (p <0.001). Regarding the antioxidant profile, in GO3, at moments B and C,
there was a significant increase in TAC (p = 0.017 and p = 0.022) and a reduction of MDA
concentration (p = 0.002 and p <0.001). In the analysis of clinical-pathological parameters
related to the survival of dogs, there was a significant association in the univariate and
multivariate analysis with quality of life, TAC, ozone therapy and MDA. The same ozone
therapy analyses showed a significant association with total leukocytes, segmented neutrophils,
quality of life, survival, TAC and MDA. The survival rate submitted to integrative treatment
was also significantly higher (p = 0.0224) than those treated only with carboplatin. These
results, together, indicate that the association between carboplatin and the mixture of oxygen
and ozone represents a feasible alternative to complementary treatment for mammary cancer
dogs as the patient's antioxidant profile positively reduces the intensity and frequency of
Adverse reactions to chemotherapy, which contributes to increased quality of life and survival
rate.
Given the high frequency of malignant mammary tumours, the search for new therapeutic
strategies that place growth control and neoplastic dissemination with lower adverse reactions
to the patient is growing. In this context, it aimed to evaluate the effects of medicinal ozone as
integrative therapy on the oxidative profile, response to treatment and quality of life with
mammary neoplasia undergoing conventional chemotherapy with carboplatin. Twenty -five
dogs were selected and studied, all with histopathological diagnosis of malignant mammary
neoplasia, divided into two experimental groups: GC, composed of carboplatin only (n = 11)
and GO3 - consisting of the carboplatin-treated dogs associated with ozone therapy (n = 14).
All dogs were submitted to clinical, laboratory, mastectomy, clinical-pathological
characterization of the tumour, carboplatin chemotherapy (QT), total oxidizing capacity
analysis (TAC), malondialdehyde concentration (MDA), as well as the evaluation of the
Survival, rate quality of life scores and graduation of adverse reactions resulting from
chemotherapy. Blood samples for antioxidant profile evaluations were collected 48 hours
before the first chemotherapy session (moment A), 48h before the fourth session (moment B)
and 45 days after the sixth chemotherapy session (moment C). Adverse reactions and quality
of life scores were evaluated two h before each session. The results indicated, in the GO3, the
highest concentration of red blood cells after the 2nd QT session (p = 0.017) and platelets after
the 2nd (p = 0.046), 3rd (p = 0.009) and 6th (p = 0.004) QT sessions; In the GC group, total
leukocyte values in the 1st Qt (p = 0.001), 3rd Qt (p = 0.038), 4th (p = 0.030), 5th Qt (p = 0.018)
and 6th qt (p = 0.006) and segmented neutrophils after the 1st Qt (p = 0.001), 2nd Qt (p =
0.018), 3rd Qt (P = 0.049), 5th Qt (p = 0.006) and 6th Qt (p = 0.016). There was an increase in
quality of life in both groups. Differences were observed between the quality-of-life scores
between the groups and within each group, being the largest final scores observed in the GO3
group in the 2nd QT (p = 0.002), 4th QT (p = 0.005), 5th QT (p = 0.005) and 6th QT (p <0.001).
Adverse reactions, classified exclusively, were less intense and frequent in the ozone group,
such as grade I (p <0.001). Regarding the antioxidant profile, in GO3, at moments B and C,
there was a significant increase in TAC (p = 0.017 and p = 0.022) and a reduction of MDA
concentration (p = 0.002 and p <0.001). In the analysis of clinical-pathological parameters
related to the survival of dogs, there was a significant association in the univariate and
multivariate analysis with quality of life, TAC, ozone therapy and MDA. The same ozone
therapy analyses showed a significant association with total leukocytes, segmented neutrophils,
quality of life, survival, TAC and MDA. The survival rate submitted to integrative treatment
was also significantly higher (p = 0.0224) than those treated only with carboplatin. These
results, together, indicate that the association between carboplatin and the mixture of oxygen
and ozone represents a feasible alternative to complementary treatment for mammary cancer
dogs as the patient's antioxidant profile positively reduces the intensity and frequency of
Adverse reactions to chemotherapy, which contributes to increased quality of life and survival
rate.
